ABP-745

N/A

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameABP-745
Drug Alias NameABP-745
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitors
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsInflammationAtherosclerosisCardiovascular Diseases +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Atom Bioscience and Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAtom Therapeutics Co LtdJiangsu Atom Bioscience and Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsInflammationAtherosclerosisArthritis, Gouty +[4] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A